High intensity focused ultrasound: The fundamentals, clinical applications and research trends

Elhelf, Islam; Albahar, Hadeel; Shah, Umesh; Oto, A.; Cressman, Erik N.K.; Almekkawy, Mohamed

doi:10.1016/j.diii.2018.03.001

Cited by 176 publications

(110 citation statements)

References 93 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…With ultrasound guidance, HIFU accurately triggers coagulation necrosis at the target lesion without damaging the adjacent normal tissue. Compared to open surgery, HIFU offers fewer complications, quicker recovery, shorter hospitalization and better quality of life [10]. However, previous studies have also shown that approximately 20% of patients had recurrences soon after HIFU ablation [11,12]; thus, it is crucial to explore new therapeutic schedule to achieve lower recurrence rate.…”

Section: Introductionmentioning

confidence: 99%

Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis

Yang

Zhang

Lin

et al. 2019

International Journal of Hyperthermia

View full text Add to dashboard Cite

Objective: To evaluate the combined efficacy of high-intensity focused ultrasound (HIFU), gonadotropin-releasing hormone agonist (GnRH-a) and the levonorgestrel-releasing intrauterine system (LNG-IUS) for the treatment of severe adenomyosis. Method: Four hundred and sixty-six patients with adenomyosis admitted to the Department of Gynecology of Shanghai First Maternity and Infant Hospital underwent HIFU treatment, and then were consecutively administered with GnRH-a 1 d, 1 month and 3 months after HIFU treatment. The uterine size was then measured with ultrasound or MRI 2-4 weeks after three cycles of GnRH-a injection. The LNG-IUS was then inserted when the uterine length less than 9 cm. The visual analog scale (VAS), verbal rating scale (VRS), menstrual volume score, uterus volume, MRI, serum levels of hemoglobin and CA125 were measured at pre and 3-, 6-, 12-month post-HIFU. Results: Dysmenorrhea and menorrhagia significantly relieved after combined treatment with HIFU, GnRH-a and the LNS-IUS. The uterine volume shrank and returned to its normal size. The serum CA-125 level was reduced to the normal level after the combined treatment. Conclusions: The combined therapeutic regimen of HIFU, GnRH-a and LNS-IUS is safe, effective and efficient for curing severe adenomyosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis

Yang

Zhang

Lin

et al. 2019

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…HIFU, known as ultrasound hot removal, has been used clinically . By focusing the low‐energy ultrasound into a higher‐energy focus, the tumor tissue is heated to more than 60 °C to form irreversible thermal damage.…”

Section: Tumor Therapymentioning

confidence: 99%

Nanoscale Metal‐Organic Frameworks: Synthesis, Biocompatibility, Imaging Applications, and Thermal and Dynamic Therapy of Tumors

Tan

Meng

2020

Adv Funct Materials

132

View full text Add to dashboard Cite

Nanoscale metal‐organic frameworks (NMOFs) have attracted increasing attention for biomedical applications due to their large specific surface area, good biocompatibility, adjustable structures, and diverse functions. By choosing appropriate metal ions and ligands, NMOFs can be synthesized and regulated to assist the diagnosis and treatment of cancer, acting as imaging agents, drug carriers, and cancer therapeutic agents. This review summarizes the recent advances of NMOFs in synthesis, biocompatibility, imaging, and applications in cancer therapies. Among these, the term “biocompatibility” is used to outline their various biological characteristics, and it is mainly discussed from the aspects of size and surface properties of NMOFs. The imaging section mainly emphasizes the application advantages of NMOFs as imaging agents in magnetic resonance, computed tomography, and fluorescence imaging. The applications of NMOFs in four cancer therapies, including phototherapy, radiotherapy, microwave therapy, and ultrasonic therapy, are addressed, especially for thermal and dynamic therapy. Finally, the prospects and challenges of NMOFs in imaging and cancer therapies are also discussed.

show abstract

“…Depending on the settings, thermal or mechanical effects can be induced, known as thermal ablation or histotripsy. So far, HIFU is approved by the FDA for six indications, including uterine fibroids, benign and malignant prostate lesions, essential tremor, tremor dominant Parkinson's disease, and bone metastases [162].…”

Section: Status Quomentioning

confidence: 99%

What scans we will read: imaging instrumentation trends in clinical oncology

et al. 2020

View full text Add to dashboard Cite

Oncological diseases account for a significant portion of the burden on public healthcare systems with associated costs driven primarily by complex and long-lasting therapies. Through the visualization of patient-specific morphology and functional-molecular pathways, cancerous tissue can be detected and characterized noninvasively, so as to provide referring oncologists with essential information to support therapy management decisions. Following the onset of stand-alone anatomical and functional imaging, we witness a push towards integrating molecular image information through various methods, including anato-metabolic imaging (e.g., PET/ CT), advanced MRI, optical or ultrasound imaging. This perspective paper highlights a number of key technological and methodological advances in imaging instrumentation related to anatomical, functional, molecular medicine and hybrid imaging, that is understood as the hardware-based combination of complementary anatomical and molecular imaging. These include novel detector technologies for ionizing radiation used in CT and nuclear medicine imaging, and novel system developments in MRI and optical as well as opto-acoustic imaging. We will also highlight new data processing methods for improved non-invasive tissue characterization. Following a general introduction to the role of imaging in oncology patient management we introduce imaging methods with well-defined clinical applications and potential for clinical translation. For each modality, we report first on the status quo and, then point to perceived technological and methodological advances in a subsequent status go section. Considering the breadth and dynamics of these developments, this perspective ends with a critical reflection on where the authors, with the majority of them being imaging experts with a background in physics and engineering, believe imaging methods will be in a few years from now. Overall, methodological and technological medical imaging advances are geared towards increased image contrast, the derivation of reproducible quantitative parameters, an increase in volume sensitivity and a reduction in overall examination time. To ensure full translation to the clinic, this progress in technologies and instrumentation is complemented by advances in relevant acquisition and image-processing protocols and improved data analysis. To this end, we should accept diagnostic images as "data", andthrough the wider adoption of advanced analysis, including machine learning approaches and a "big data" conceptmove to the next stage of non-invasive tumour phenotyping. The scans we will be reading in 10 years from now will likely be composed of highly diverse multidimensional data from multiple sources, which mandate the use of advanced and interactive visualization and

show abstract

High intensity focused ultrasound: The fundamentals, clinical applications and research trends

Cited by 176 publications

References 93 publications

Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis

Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis

Nanoscale Metal‐Organic Frameworks: Synthesis, Biocompatibility, Imaging Applications, and Thermal and Dynamic Therapy of Tumors

What scans we will read: imaging instrumentation trends in clinical oncology

Contact Info

Product

Resources

About